Feb. 19, 2010
Rondaxe and TD2 form strategic drug development alliance
TGen Drug Development (TD2) gets skills in drug manufacturing and quality control, Rondaxe receives access to TD2’s expertise in clinical trials and regulatory navigation

TD2 and Rondaxe Enterprises have announced a strategic alliance that will help emerging companies speed new high-quality treatments to cancer patients.... Read More

Jan. 21, 2010
New study shows TGen spin-off boosts Scottsdale economy
TGen Drug Development (TD2) creates jobs, revenues, related businesses; Total economic impact on the city in 2015 is projected to top $239 million

TD2 is poised to play a significant role in the expansion of Scottsdale's biomedical industry, fostering new jobs and city revenues, and prompting the creation of more related businesses... Read More

Jan. 12, 2010
TD2 and Critical Outcome Technologies Inc. develop novel anti-cancer drug
World renowned clinical oncologist and TGen Drug Development chosen to lead drug development program for COTI-2

TD2 and Critical Outcome Technologies Inc. announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2... Read More

Nov. 18, 2009
TGen Drug Development (TD2) establishes European footprint
Alliance with France's Institut Paoli-Calmettes focuses on cancer

TD2 and the Institut Paoli-Calmettes (IPC) have forged a strategic alliance that will enable both to maximize their worldwide contributions in the treatment of cancer patients... Read More

Aug. 5, 2008
Apthera and TGen Drug Development Services (TD2) Sign Master Services Agreement
TD2 to Provide Strategic Drug Development Services

Apthera, Inc., a Scottsdale, Arizona-based biotechnology company focused on cancer immunotherapy, today announced an alliance with TD2... Read More